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Purpose: Neurofibromatosis type 1 (NF1) is characterized by a
highly variable clinical presentation, but almost all NF1-affected
adults present with cutaneous and/or subcutaneous neurofibromas.
Exceptions are individuals heterozygous for the NF1 in-frame
deletion, c.2970_2972del (p.Met992del), associated with a mild
phenotype without any externally visible tumors.
Methods: A total of 135 individuals from 103 unrelated families,
all carrying the constitutional NF1 p.Met992del pathogenic variant
and clinically assessed using the same standardized phenotypic
checklist form, were included in this study.
Results: None of the individuals had externally visible plexiform or
histopathologically confirmed cutaneous or subcutaneous neurofi-
bromas. We did not identify any complications, such as sympto-
matic optic pathway gliomas (OPGs) or symptomatic spinal
neurofibromas; however, 4.8% of individuals had nonoptic brain
tumors, mostly low-grade and asymptomatic, and 38.8% had
cognitive impairment/learning disabilities. In an individual with the
NF1 constitutional c.2970_2972del and three astrocytomas, we
provided proof that all were NF1-associated tumors given loss of
heterozygosity at three intragenic NF1 microsatellite markers and
c.2970_2972del.
Conclusion: We demonstrate that individuals with the NF1
p.Met992del pathogenic variant have a mild NF1 phenotype lacking
clinically suspected plexiform, cutaneous, or subcutaneous neurofi-
bromas. However, learning difficulties are clearly part of the
phenotypic presentation in these individuals and will require
specialized care.
Genetics in Medicine (2019) 21:867–876; https://doi.org/10.1038/s41436-
018-0269-0
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INTRODUCTION
Neurofibromatosis type 1 (NF1, MIM 162200) is an
autosomal dominant disorder affecting 1 in every 2000 to
3000 births with age-dependent penetrance and highly
variable inter- and intrafamilial expressivity.1 The main
clinical signs of NF1 include café-au-lait macules (CALMs),
skinfold freckling, Lisch nodules, neurofibromas, optic path-
way gliomas (OPGs), and/or specific skeletal abnormalities,
such as sphenoid wing or tibial dysplasia. According to the
diagnostic criteria established by the National Institutes of
Health (NIH), the presence of at least two of the aforemen-
tioned features (or a single clinical symptom with a first-
degree relative meeting NIH criteria) is sufficient for a clinical
diagnosis of NF12. The NIH diagnostic criteria are highly
specific and sensitive in NF1-affected adults as nearly all have
cutaneous and/or subcutaneous neurofibromas.3 Examples of
individuals consistently presenting only with typical pigmen-
tary manifestations (multiple CALMs with/without freckling)
without externally visible plexiform, cutaneous, or subcuta-
neous neurofibromas are these heterozygous for the NF1
deletion p.Met992del and missense pathogenic variants at
residue p.Arg18094–6. Because NF1 is a progressive disorder
with phenotypic manifestations increasing with age, the
development of serious complications still needs considera-
tion in individuals with p.Met992del until more data,
especially in adults, have become available. The association
of p.Met992del with a mild phenotype was originally
established based on the analysis of 21 unrelated probands
and 26 affected relatives, with only 19 individuals ≥19 years
old.4 Larger data sets, preferably of adults, are required to
confirm the mild clinical course in these individuals and
identify rare complications.
We describe in this study detailed phenotypic characteriza-
tion of an additional 135 individuals from 103 unrelated
families carrying the NF1 p.Met992del pathogenic variant.
Besides confirming the absence of superficial neurofibromas,
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we demonstrate that some complications, such as nonoptic
brain tumors and cognitive impairment and/or learning
disabilities, are present in a significant number of these
individuals (4.8% and 38.8%, respectively). We also provide
proof of the existence of low-grade pilocytic astrocytomas
with the NF1 p.Met992del pathogenic variant and loss of
heterozygosity (LOH) at p.Met992del and three intragenic
NF1 microsatellite markers in three lesions from a single NF1-
affected individual, establishing these as NF1-associated
tumors.
MATERIALS AND METHODS
A total of 135 individuals from 103 unrelated families were
referred to the Medical Genomics Laboratory at University of
Alabama at Birmingham (UAB; 74 probands and 27 affected
relatives) and collaborating centers (EUR; 29 probands and
5 affected relatives) for NF1 molecular testing (see details
in Table S1). All were confirmed as having the same NF1
3-bp in-frame deletion c.2970_2972del, leading to loss of
a methionine at codon 992 (p.Met992del), except for a
14-month-old girl heterozygous for the NF1 c.2974_2976del,
also resulting in p.Met992del (UAB-R7536). Comprehensive
NF1 molecular analysis with an RNA-based approach was
performed in the Medical Genomics Laboratory as previously
described,6,7 with LRG_214 and NM_000267.3 used as the
reference sequences.
Clinical data were collected as previously reported6,7 at the
time of genetic testing with data reverified by referring
physicians for accuracy and/or updating, when available.
As magnetic resonance imaging (MRI) is not routinely
performed in individuals without clinical signs/suspicion
for spinal neurofibromas and/or OPGs, presence of internal
neurofibromas and asymptomatic OPGs could not be
excluded in all cases. If ≥2 Noonan-like features (i.e., short
stature, facial dysmorphism [low-set ears, hypertelorism,
downslanted palpebral fissures, midface hypoplasia, ptosis,
and/or webbed neck] or cardiac abnormality [pulmonic
stenosis]) were present, an individual was classified as having
Noonan-like phenotype. Short stature and macrocephaly were
defined as previously described.6,7
We compared the phenotypes of individuals with the NF1
p.Met992del pathogenic variant with the cohorts of indivi-
duals heterozygous for the NF1 missense pathogenic variants
affecting codons 1809 and 844–848 5–10, and previously
described large-scale cohorts with “classic” NF111–24. Two-
tailed Fisher’s exact test with P values adjusted for multiple
comparisons using Benjamini–Hochberg (B–H) procedure
with false discovery rates (FDR) at 0.05 and 0.01 was applied
(GraphPad software; Table S2).
This study was approved by the institutional review boards
of all participating institutions offering clinical genetic testing.
RESULTS
Clinical description of the studied group
Among 103 unrelated probands, 38/103 (36.9%) were familial
and 43/103 (41.8%) were sporadic cases, with 6/43 individuals
Table 1 Demographic and clinical characterization of
individuals with the NF1 p.Met992del pathogenic variant
NF1 feature N (%)
≤8
years
9–18
years
≥19
years
All
ages
Mutation-positive individuals
[proband:relative]
45
[41:4]
50
[43:7]
40
[19:21]
135
[103:32]
Male:female 15:30 27:23 18:22 60:75
Fulfilling the NIH criteria if the family
history is taken into account
31/43
(72.1)
43/49
(87.8)
23/39
(59)
97/131
(74.1)
Fulfilling the NIH criteria if solely
taking the physical signs into
account
20/43
(46.5)
36/49
(73.5)
20/39
(51.3)
76/131
(58)
>5 CALMs 41/45
(91.1)
48/50
(96)
30/40
(75)h
119/
135
(88.2)
Skinfold freckling 20/39
(51.3)
35/48
(72.9)
18/37
(48.7)
73/124
(58.9)
Lisch nodules 3/34
(8.8)
6/43
(14)
4/24
(16.7)
13/101
(12.9)
Skeletal abnormalitiesa 5/39
(12.8)
9/48
(18.8)
7/38
(18.4)
21/125
(16.8)
Major external plexiform
neurofibromas
0/44
(0)
0/46
(0)
0/38
(0)
0/128
(0)
Cutaneous neurofibromasb 0/43
(0)
0/47
(0)
0–1/38
(0–2.6)i
0–1/128
(0–0.8)
Subcutaneous neurofibromasb 0/42
(0)
0/46
(0)
0–3/36
(0–8.3)i
0–3/124
(0–2.4)
Symptomatic spinal neurofibromas 0/39
(0)
0/45
(0)
0/34
(0)
0/118
(0)
Symptomatic OPGsc 0/43
(0)
0/47
(0)
0/33
(0)
0/123
(0)
Asymptomatic OPGsd 0/11
(0)
1/19
(5.3)
0/11
(0)
1/41
(2.4)
Other neoplasmse 0/42
(0)
5/47
(10.6)
8/37
(21.6)
13/126
(10.3)
Cognitive impairment and/or
learning disabilities
14/42
(33.3)
24/49
(49)
12/38
(31.6)
50/129
(38.8)
Noonan-like featuresf 3/42
(7.1)
6/43
(14)
6/34
(17.7)
15/119
(12.6)
Short statureg 2/24
(8.3)
6/32
(18.8)
3/15
(20)
11/71
(15.5)
Macrocephaly 12/32
(37.5)
8/40
(20)
6/15
(40)
26/87
(29.9)
Pulmonic stenosis 3/38
(7.9)
1/44
(2.3)j
0/31
(0)
4/113
(3.5)
CALMs, café-au-lait macules; NF1, neurofibromatosis type 1; NIH, National Insti-
tutes of Health; OPG, optic pathway glioma.
aAll bone abnormalities included, that is, scoliosis (n= 11), pectus abnormality
(n= 9), mild winging of the scapula (n= 1), rib abnormality (n= 1), dysplastic
vertebrae (n= 1), kyphosis (n= 1), and bilateral club feet (n= 1).
bAt least two cutaneous/subcutaneous neurofibromas were required to be
considered as “positive for the criterion of neurofibromas.”
cThe absence of symptomatic OPGs was determined by ophthalmological exam-
ination and/or by magnetic resonance image (MRI).
dIncluding only individuals without signs of symptomatic OPGs who underwent
MRI examination.
eAll “other” neoplasms, not including OPGs and neurofibromas, included, that is,
astrocytomas (n= 3), oligodendroglioma (n= 1), lipomas (n= 5), angiolipoma
(n= 1), hypothalamic glioma (n= 1), brain tumor with hamartomatous aspect
by MRI of the encephalon (n= 1), neuroblastoma (n= 1), and craniopharyngioma
(n= 1).
fAn individual was classified as having Noonan-like phenotype when at least two
of the following features were present: short stature, low-set ears, hypertelorism,
downslanted palpebral fissures, midface hypoplasia, ptosis, webbed neck, and/or
pulmonic stenosis.
gAs no specific growth curves are available for the Hispanic and Asian popula-
tions, Hispanic and Asian individuals were excluded as having short or normal sta-
ture.
hA possible explanation for a decreasing prevalence of CALMs in individuals
≥19 years is the fact that CALMs become fainter with age and some may even
disappear entirely.
iFour individuals with few (2–6) cutaneous or subcutaneous “neurofibromas”;
none were biopsied and therefore none have been histologically confirmed.
jThe presence of pulmonic stenosis was reported in the individual’s newborn
period.
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proven to have a de novo variant, but no formal paternity/
maternity testing was performed. Two individuals with proven
de novo p.Met992del (UAB-R6151 and UAB-R2586) had one
parent reported to have 1–5 CALMs with/without freckling;
thus gonosomal mosaicism or the presence of a different
independent NF1 pathogenic variant cannot be excluded in
these families (Table S1). For 22/103 (21.4%) cases family
history was unknown, including three adopted probands.
Ninety-seven of 131 individuals (74.1%) fulfilled the NIH
diagnostic criteria, but only 76/131 (58%) if family history was
excluded as a criterion (Table 1). Of the 55 cases not fulfilling
the NIH diagnostic criteria after excluding the family history,
31 had complete clinical information including the ophthal-
mological results for the presence/absence of Lisch nodules
and symptomatic OPGs (Table S1 and Table S3), including
11/31 (35.5%) children ≤8 years old, 10/31 (32.3%) indivi-
duals between 9 and 18 years old, and 10/31 (32.3%) adults
over 19 years old. Five of 31 individuals had <6 CALMs as the
only clinical feature (Table S3).
The presence of >5 CALMs and freckling was observed in
119/135 (88.2%) and 73/124 (58.9%) cases, respectively. Fifty-
two of 85 individuals ≥9 years old had both pigmentary
manifestations, while Lisch nodules were observed in 12.9%
(13/101) of the studied cohort, including 14.9% (10/67)
≥9 years old. No symptomatic OPGs were found herein
(0/123); however, of 41 asymptomatic individuals receiving
brain MRI screening, a single bilateral OPG located in chiasm
and optic nerves was reported (EUR-R1).
No histopathologically confirmed externally visible plexi-
form (0/128, including 0/84 individuals ≥9 years old),
cutaneous (0/128, including 0/38 individuals ≥19 years),
or subcutaneous neurofibromas (0/124, including 0/36
individuals ≥19 years) were found. In 14 cases ≥14 years a
single or a few cutaneous or subcutaneous lesions suspected
to be neurofibromas were observed (Table S1 and Table S4).
Importantly, for five individuals the diagnosis was “lipoma”
instead after detailed clinical and/or histopathological analy-
sis. Symptomatic spinal neurofibromas were absent in all 118
individuals and the presence of asymptomatic spinal tumors
was excluded by MRI in 13 cases (with 12/13 individuals
≥9 years old).
Twenty-one of 125 individuals (16.8%) had skeletal
abnormalities (Table 1 and Table S1). Besides scoliosis
(11/125 all ages, but 5/38 ≥19 years) and pectus anomalies
(9/125), other skeletal abnormalities included rib abnormality,
bilateral club feet, dysplastic vertebrae, mild winging of the
scapula and kyphosis (each observed in a single individual).
Nonmalignant tumors, not including OPGs and neurofi-
bromas, were identified in 12/126 (9.5%) individuals and
included astrocytomas (n= 3, one tumor was described as
having features of astrocytoma and dysembryoplastic neu-
roepithelial tumor [DNET], see details in Table S1), oligoden-
droglioma (n= 1), lipomas (n= 5), angiolipoma (n= 1),
hypothalamic glioma (n= 1), brain tumor with hamartoma-
tous aspect by MRI of the encephalon (n= 1), and
craniopharyngioma (n= 1) (Table 1). In addition, one
individual had a history of a neuroblastoma, but detailed
follow-up was not available (Table S1 and Table S5). No
breast cancer was observed in the studied cohort (0/20 women
≥19 years). Of particular interest was a 42-year-old male
with no clinical signs of NF1 (UAB-R5571-F) and no history
of prior irradiation, but with three surgically removed
juvenile pilocytic astrocytomas, one located in the brainstem
and two in the top left side of the brain (Table S1). He was
molecularly diagnosed as being heterozygous for NF1
p.Met992del after diagnosis was made in his son who had
>5 CALMs, left inguinal freckling, macrocephaly, and
abnormal development (Fig. S1). Morphologically, an astro-
cytic neoplasm composed of two growth patterns was
observed, i.e., areas with a fibrillary arrangement and
Rosenthal fibers and areas with a pattern similar to that seen
in oligodendroglioma; there was no significant pleomorphism,
increased mitotic activity, or necrosis. Molecular analysis
revealed the NF1 pathogenic variant c.2970_2972del with
LOH at c.2970_2972del and all three intragenic NF1
microsatellite markers tested in all three astrocytomas,
confirming these as NF1-associated tumors.
Fifty of 129 case subjects (38.8%) had an abnormal
development with at least one of the following forms of
cognitive impairment or learning disabilities: learning
difficulties (n= 38), developmental delay (n= 10), speech
delay (n= 15), motor delay (n= 7), autism spectrum
(n= 1), or psychiatric problems (n= 2). Of these, three
individuals (UAB-R1873, UAB-R1873-M, and UAB-R6975)
carried known additional genomic imbalances: 1q21.1
deletion (MIM 612474), 12q23.2 duplication, and 15q13.3
duplication (Table S1 and Fig. S2). In addition, array
comparative genomic hybridization (aCGH) analysis revealed
the presence of a 12.6-kb-sized deletion on 16p13 and 226.9
kb-sized duplication on 14q32.13 of unclear clinical signifi-
cance in a single individual (UAB-R8603) (Table S1).
Noonan-like features were found in 15/119 (12.6%) indivi-
duals, including the presence of pulmonic stenosis in four
children ≤8 years old. In all 10 individuals with Noonan-like
phenotype referred to UAB no pathogenic or likely patho-
genic variants in 16 Noonan-related disorder genes (see
details in Table S1) were identified. Other cardiovascular
abnormalities included hypertension, double aortic arch with
vascular ring, ventricular tachycardia, sinus arrhythmia
and atypia of repolarization, and atrial septal defect (each
observed in a single individual). Short stature and macro-
cephaly were found in 11/71 (15.5%) and 26/87 (29.9%) of
case subjects, respectively.
Comparison of clinical features in individuals heterozygous
for NF1 p.Met992del with cohorts of individuals with NF1
missense pathogenic variants affecting codons 1809 and
844–848 and with “classic” NF1 phenotype
Individuals with p.Met992del had Lisch nodules significantly
less often and no externally visible plexiform neurofibromas,
cutaneous and subcutaneous neurofibromas, compared with
the cohort of individuals with the NF1 missense pathogenic
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variants at residues 844–848 and previously reported “classic”
NF1 population (all P < 0.0001, statistically significant after
B–H correction at FDR 0.01; Table 2). Importantly, no
individuals described in this and previous studies had visible
plexiform neurofibromas (0/127 ≥9 years) or histopathologi-
cally confirmed cutaneous (0/59 ≥19 years) or subcutaneous
neurofibromas (0/37 ≥19 years) (Table S6).4,25,26 Similar to
the NF1 p.Arg1809 cohort, no symptomatic OPGs were
observed in the studied group. In the current study, none of
the individuals showed symptomatic spinal neurofibromas
(Table 1), although in the original report a single sympto-
matic spinal tumor was found;4 nevertheless, even combined
that remains significantly less prevalent than in the cohort of
individuals with the NF1 missense pathogenic variants at
residues 844–848 (P < 0.0001, statistically significant after
B–H correction at FDR 0.01).
The mild phenotype without any externally visible neurofi-
bromas observed in the current study is therefore similar to
that of individuals with the NF1 p.Arg1809 missense
pathogenic variants, except for the presence of brain tumors
being more prevalent in the p.Met992del-positive cohort
(4.8% versus 0.8%), but this difference was not statistically
significant (P= 0.0640).
The prevalence of skeletal abnormalities was similar as in
the NF1 p.Arg1809 cohort and “classic” NF1 population
(17.4% versus 16.7% versus 15.2%, respectively), but lower
than in the cohort of individuals with the NF1 missense
pathogenic variants at residues 844–848 (P= 0.0016, statis-
tically significant after B–H correction at FDR 0.05).
Noonan-like features and pulmonic stenosis were much
more prevalent in the studied group compared with the
general NF1 population (P < 0.0001 and P= 0.0009, respec-
tively, both statistically significant after B–H correction at
FDR 0.01). However, compared with the p.Arg1809 cohort,
individuals with p.Met992del had Noonan-like phenotype
and short stature statistically less often (P < 0.0001 and P=
0.0056, statistically significant after B–H correction at FDR
0.01 and 0.05, respectively; Table 2). In addition, macro-
cephaly was observed less frequently than in the cohorts of
individuals with the NF1 missense pathogenic variants
at residues 844–848 and “classic” NF1 clinical presentation
(P= 0.0267 and P= 0.0111, respectively, not statistically
significant after B–H correction at FDR 0.05; Table 2).
Finally, individuals with p.Met992del had a significantly
lower prevalence of cognitive impairment and/or learning
disabilities compared with the cohorts of individuals with
the NF1 missense pathogenic variants at codon 1809 and the
general NF1 population (P= 0.0018 and P= 0.0082, both
statistically significant after B–H correction at FDR 0.05;
Table 2). Comparing the current cohort with the initially
reported p.Met992del individuals,4 the overall frequency of
abnormal development with/without learning disabilities
was significantly higher in the current study (38.8% versus
17%; P= 0.0066; Table S7), even after excluding the
individuals with genomic imbalances that may have a
modifying effect (36.8% versus 17%; P= 0.0160; Table S7).
DISCUSSION
A renewed interest in NF1 genotype–phenotype correlations is
emerging, especially with the rapid development and accessi-
bility of genomic technology, given the recent identification of
four clinically significant genotype–phenotype correlations.4–7,27
The constitutional NF1 microdeletion and NF1 missense
pathogenic variants affecting codons 844–848 are important
risk factors for severe presentation, including a high prevalence
of plexiform neurofibromas at an earlier age, dysmorphic
facial features and global developmental delay with/
without learning disabilities and an increased lifetime risk for
malignant peripheral nerve sheath tumors (MPNSTs) in
individuals with the NF1 microdeletion,27 and a significant
increase in number of plexiform and symptomatic spinal
neurofibromas, symptomatic OPGs, skeletal abnormalities,
and malignant neoplasms in individuals with the NF1 missense
pathogenic variants at residues 844–8487. Furthermore, a
mild clinical presentation lacking any externally visible plexi-
form, cutaneous, or subcutaneous neurofibromas is observed
in NF1-affected individuals heterozygous for the NF1 missense
pathogenic variants at codon 18095,6 or the 3-bp in-frame
NF1 deletion, c.2970_2972del (p.Met992del).4 Because the
latter genotype–phenotype correlation was established on a
limited number of NF1-affected adults (19/47), an update of
this initial intragenic genotype–phenotype correlation is
important for clinical practice.
The frequency of the p.Met992del pathogenic variant in the
NF1 mutation–positive unrelated individuals from the UAB
cohort is ~0.9% (74/8400), making it one of the most
common recurring variants observed in the UAB database.
This variant was reported in publicly available disease
databases (last accessed July 2018), such as the Leiden Open
Variation Database (LOVD; 28 times, 27/28 and 1/28
classified as pathogenic and likely pathogenic, respectively),
ClinVar (7 times, all classified as pathogenic) and the Human
Gene Mutation Database (HGMD; classified as pathogenic)
and absent in population databases, 1000 Genomes, and the
Exome Variant Server (EVS), except for a single report in the
Genome Aggregation Database (gnomAD; the variant’s
frequency in all populations is 0.00041%), and completely
segregated with the disorder in 14 affected individuals from
12 unrelated families and was proven to be de novo in
six probands. As such, the NF1 deletion, c.2970_2972del
(p.Met992del), should undoubtedly be classified as pathogenic
according to current recommendations.28
Cutaneous and subcutaneous neurofibromas are benign
tumors located on or just under the skin, typically developing
around puberty, and almost all NF1-affected adults have at
least several of them.16 Over the course of time, the number of
neurofibromas usually increases, varying from hundreds to
thousands. Plexiform neurofibromas may be recognized
earlier as they may occur congenitally, but most of them
grow slowly, with externally visible plexiform neurofibromas
becoming apparent in the early years of life. Plexiform
neurofibromas arise in peripheral nerves and are clinically
suspected in 15–30% of the NF1-affected general population,
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but the prevalence of the internal tumors is higher.3,11,18,29–31
Moreover, plexiform and subcutaneous neurofibromas are
associated with an increased lifetime risk for the development
of MPNSTs, resulting in significant morbidity for these
individuals.32–34 From a clinical point of view, it is important
to identify early those individuals with an increased risk to
develop malignancies so as to provide them personalized
management and genetic counseling.
In the current study, we confirmed the paucity of superficial
plexiform (0/84 ≥9 years) and cutaneous neurofibromas
(0/38 ≥19 years), in line with the original report.4 None of the
individuals had externally visible plexiform neurofibromas or
histopathologically confirmed cutaneous or subcutaneous
neurofibromas (all P < 0.0001, statistically significant at FDR
of 0.01 after B–H correction when compared with the cohort
of individuals with the NF1 missense pathogenic variants
affecting codons 844–848 and the “classic” NF1-affected
population, Table 2). Combining data from this and previous
studies4,25,26 for plexiform (0/127 ≥9 years), cutaneous, and
subcutaneous neurofibromas (0/59 and 0/37 ≥19 years,
respectively), we estimate in post hoc power calculation that
these sample sizes would allow to detect the presence of
plexiform, cutaneous, and subcutaneous neurofibromas with
a prevalence of at least 3%, 7%, and 10%, respectively with
a power of 95%. However, we cannot speculate about the
risk for internal neurofibromas in this cohort as MRI
screening was not routinely done in most of the asymptomatic
individuals.
The presence of possible few cutaneous or subcutaneous
lesions was initially mentioned on the phenotypic checklist in
14 individuals ≥14 years, but upon further detailed clinical
evaluation by NF1 experts and/or histopathological analysis
the lesions were diagnosed as lipomas in 5/14 individuals
(for the remaining cases no follow-up was available)
(see Comments in Table S1 and Table S4). Moreover, in
none of the individuals were additional lesions observed over
time, further supporting that these lesions were unlikely to
be neurofibromas, because cutaneous and subcutaneous
neurofibromas usually increase in number over the years.
The overall prevalence of lipomas in the p.Met922del-positive
individuals from this and a previous study4 was 5.5% (7/128);
lipomas have also been observed in ~20% of individuals
(21/115) with Legius syndrome (MIM 611431), another mild
phenotype consisting of pigmentary spots only, caused by
pathogenic variants in SPRED1 (MIM 609291).35
Besides neurofibromas and OPGs, NF1-affected individuals
may develop other benign and malignant tumors, such as
MPNSTs, rhabdomyosarcomas, leukemias, neuroblastomas,
pheochromocytomas, gastrointestinal stromal tumors
(GISTs), glomus tumors, and breast and/or ovarian cancer36
that depending on the clinical and histological grade may
significantly increase mortality in the NF1 population.1
Nonoptic gliomas are one of the most common brain tumors
in NF1-affected individuals, with an overall frequency greater
than 100 times that in the general population.37 In the current
study, we reported 6/126 (4.8%) individuals with nonoptic
brain tumors, mostly low-grade and asymptomatic (Table S1
and Table S5). The prevalence in the studied cohort was
similar to that recorded in the recent report on nonoptic
gliomas by Sellmer et al.38 (24/562, 4.3%). Additionally, we
confirmed the presence of the NF1 p.Met992del pathogenic
variant with LOH in three astrocytomas from a single case
(UAB-R5571-F), confirming these as NF1-associated tumors.
Burgoyne et al.26 also demonstrated the occurrence of a
germline p.Met992del along with a somatic NF1
p.Ser1407fs*21 pathogenic variant in an individual with
multiple CALMs and mild axillary freckling who developed
a low-grade GIST. Notwithstanding the above, brain tumors
seem to be the most common complications in individuals
heterozygous for the constitutional NF1 p.Met992del. Even
though brain tumors in NF1 usually are low-grade lesions and
have a more benign course than in the individuals without
NF139, it is important that clinicians involved in the care of
individuals with NF1 are aware of this complication.
The highly variable inter- and intrafamilial expressivity and
age-dependency of most symptoms undoubtedly hampers the
accurate NF1 clinical diagnosis, especially in infants and
individuals with mosaic NF1. Indeed, nearly half of sporadic
NF1-affected children do not fulfill the NIH diagnostic criteria
by 1 year of age.3 In this study, we observed that 14/60 (23.3%)
of individuals ≥9 years did not fulfill the NIH diagnostic criteria.
However, these numbers increase dramatically if the family
history is not taken into account (23/60, 38.3%), which
necessarily applies to all sporadic cases (Table S8). An
important reason why the p.Met992del-positive individuals
do not fulfill NIH criteria is the absence of any externally
visible neurofibromas, even in adults. As only 10/67 (14.9%)
of individuals ≥9 years developed Lisch nodules (Table 1), a
systematic ophthalmological examination for Lisch nodules
may not be of major help in making an early clinical diagnosis
in the p.Met992del-positive individuals. The cumulative
advances in our understanding of NF1 prompt the need to
consider if additional clinical signs, such as juvenile
xanthogranulomas (JXG), nevus anemicus (NA), or choroidal
abnormalities, as well as proof of a pathogenic variant, may
help to establish an early NF1 diagnosis, especially in
children.40 However, screening for JXG, NA, and choroidal
abnormalities was not routinely done in the current study.
Cognitive impairment and/or learning disabilities are part
of the phenotype associated with the NF1 p.Met992del, as
these were present in 50/129 individuals (38.8%), including
five children with severe global developmental delay and/or
gross motor delay (UAB-R1542, UAB-R1873, UAB-R4613,
UAB-R6975, and UAB-R4846). In some cases, aCGH analysis
was performed in addition to the NF1 molecular analysis,
identifying genomic imbalances that may have modifying
roles (Table S1). One of these cases (UAB-R6975), a 9-year-
old girl with serious neurocognitive issues (severely deficient
verbal intellectual function, impaired expressive and receptive
language delays, and features of autism spectrum disorder,
generalized anxiety disorder, and dyspraxia), was found to
have a constitutional 15q13.3 duplication, encompassing the
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CHRNA7 (MIM 118511) and OTUD7A (MIM 612024) genes
(Table S1). CHRNA7 duplication is however of unknown
significance, although cognitive impairment and psychiatric
disorders have been observed in several families with such
microduplications.41 On the other hand, another individual
(UAB-R4613) also with very severe developmental delay
(inability to read and write at age 17 and only processing basic
information, such as following directions and completing
small assignments) had a normal aCGH result. Nevertheless,
compared with the initial study,4 abnormal development
with/without learning disabilities was much more common
in the current study (P= 0.0066; Table S7) and requires
special attention.
Furthermore, Noonan-like phenotype and pulmonic steno-
sis were more frequent in the studied cohort compared with
the general NF1 population (P < 0.0001 and P= 0.0009,
respectively; both statistically significant at FDR of 0.01 after
B–H correction); however, 2/15 individuals showed presence
of the 1q21.1 microdeletion syndrome (Fig. S2), which is
associated with some Noonan-like features. Pathogenic or
likely pathogenic variants in PTPN11 (MIM 176876) and/or
other Noonan-related disorder genes were ruled out in 13/15
cases with Noonan-like phenotype; two individuals (EUR-R5
and EUR-R19) were not tested (Table S1).
Although the initial genotype–phenotype report, demon-
strating very mild phenotype in the NF1 p.Met992del-
positive individuals, was published a decade ago,4 the
biological reasons why these specific individuals do not
develop any externally visible neurofibromas are still
unclear. Methionine at codon 992 is surrounded by
evolutionarily highly conserved amino acids, but no
significant progress has been made toward better under-
standing of this region of the protein. Besides the well-
understood role of the GAP-related domain, only a few
functional studies have verified how other domains regulate
the function of neurofibromin.42 Therefore, there is a need
to increase efforts to develop functional assays to improve
our understanding of the biological effect of this and other
pathogenic variants. Understanding the molecular mechan-
isms whereby p.Met992del is not associated with the
development of neurofibromas in NF1-affected individuals
may help to identify new therapeutic targets.
The mild phenotype described herein with mainly pigmentary
manifestations only is not limited to NF1 because several other
conditions with overlapping features, especially Legius syndrome
and Noonan syndrome with multiple lentigines (formerly called
LEOPARD syndrome, MIM 151100), may be phenotypically/
clinically indistinguishable from the p.Met992del or p.Arg1809
phenotypes. As such, the 2016 American Association for Cancer
Research (AACR) Childhood Cancer Predisposition workshop
recommends that children fulfilling one or more NIH diagnostic
criteria have the NF1 diagnosis molecularly confirmed.43
Establishing a correct NF1 diagnosis, especially in young
individuals who do not meet the clinical criteria, is crucial in
determining appropriate clinical management. Though
genotype–phenotype correlations are exceptions in NF1, the
identification of clinically relevant genotype–phenotype correla-
tions facilitates counseling and surveillance of a significant
number of NF1 patients.
In conclusion, we clearly confirmed that a 3-bp in-frame
deletion of the NF1 gene, c.2970_2972del (p.Met992del), is
associated with a mild phenotype lacking externally visible
plexiform, cutaneous, or subcutaneous neurofibromas.
Through the analysis on a well-described cohort of 135
individuals (including 90 individuals ≥9 years) we bring
to attention the significant risk for cognitive impairment,
learning disabilities, and nonoptic brain tumors associated
with this particular NF1 genotype. Therefore, clinicians
specializing in the care of NF1-affected individuals should be
aware of these complications, mostly occurring in oligosymp-
tomatic individuals who may, nevertheless, require persona-
lized attention for pathogenic variant-specific complications.
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PUBLISHER’S NOTE
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contained mistakes in the paper that was published online from
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by the authors in any way and corrections were implemented as
of September 17th. We apologize for the inconvenience to the
authors and their readers.
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